Stockscreener 앱 받기
32.87
0.67%
0.22
시간 외 거래:
33.18
0.31
+0.94%
전일 마감가:
$32.65
열려 있는:
$32.87
하루 거래량:
7.62M
Relative Volume:
1.72
시가총액:
$3.66B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-35.34
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
-3.12%
1개월 성능:
-22.20%
6개월 성능:
-35.42%
1년 성능:
+50.99%
1일 변동 폭
$30.56
$33.99
1주일 범위
$30.56
$35.10
52주 변동 폭
$20.83
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.87 | 3.66B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert - 24/7 Wall St.
What’s next for Viking Therapeutics? Here’s how the company can scale up. - MarketWatch
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data - MSN
Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Royal Fund Management LLC - MarketBeat
Viking Therapeutics: The Turning Point Is Not Here Yet - Seeking Alpha
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Zacks Investment Research
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week - MSN
These 10 Firms Were Last Week’s Worst Performers - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Shares Down 4.8%Here's Why - MarketBeat
Shelton Wealth Management LLC Purchases New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today - sharewise
Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.8%Here's What Happened - MarketBeat
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential - MSN
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks - MSN
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down - Yahoo Finance
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy. - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday - MSN
Viking Therapeutics Becomes Oversold (VKTX) - Nasdaq
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Viking Therapeutics’ oral-2735 could differentiate asset, says JPMorgan - MSN
International Assets Investment Management LLC Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics begins phase 2 trial for obesity drug By Investing.com - Investing.com Nigeria
Should You Buy the Dip on This High-Flying Stock? - AOL
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - The Malaysian Reserve
Viking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral - GuruFocus.com
Viking Therapeutics begins phase 2 trial for obesity drug - Investing.com
Viking Therapeutics Launches Phase 2 Trial for Oral Weight Loss Drug After Impressive Early Results - StockTitan
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Viking Therapeutics COO sells $2.3 million in stock By Investing.com - Investing.com South Africa
Viking therapeutics CEO sells $8.3 million in stock - Investing.com India
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 50,309 Shares of Stock - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells 54,215 Shares of Stock - MarketBeat
Viking therapeutics CEO sells $8.3 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CFO sells shares worth $2.15 million By Investing.com - Investing.com Nigeria
Viking Therapeutics COO sells $2.3 million in stock - Investing.com
VKTXViking Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
President & CEO Lian Brian was granted 256,133 shares and sold $8,313,601 worth of shares (194,490 units at $42.75), increasing direct ownership by 3% to 2,366,570 units (SEC Form 4) - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):